All In Biotech

Drug Trial Radar · NCT06978699

A Phase II Study Evaluating the Efficacy and Safety of XH-S003 Capsules in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

A Multicenter, Randomized, Single-blind Phase II Study Evaluating the Efficacy and Safety of XH-S003 Capsules in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

26

Actual

Start

May 21, 2025

Primary completion

Jan 21, 2026

Study completion Jan 21, 2026

Sponsor

Sponsor type
Industry
First posted
May 18, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, single-blind Phase II trial to evaluate the efficacy and safety of XH-S003 capsules in PNH patients. About 24 PNH patients will be enrolled and randomized to three dose levels and take XH-S003 capsules orally according to protocol.

Conditions

  • PNH - Paroxysmal Nocturnal Hemoglobinuria

Interventions

  • XH-S003 CapsuleDrug

    XH-S003 Capsule, Administered orally once daily, 125mg

  • XH-S003 CapsuleDrug

    XH-S003 Capsule, Administered orally once daily, 100mg

  • XH-S003 CapsuleDrug

    XH-S003 Capsule, Administered orally once daily, 50mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes of hemoglobin compared with baselineTime frame: 12 weeks from baseline

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • TianJin Medical University General Hospital

    Tianjin, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.